Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01596400 | Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years | PHASE1 | COMPLETED | 19 | — | — | May 1, 2012 | Dec 1, 2016 | Jun 17, 2024 | 12 | United States |
Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles.
| Arm | Type | Description |
|---|---|---|
| Sancuso Arm | EXPERIMENTAL | - |
| IV Granisetron Arm | ACTIVE_COMPARATOR | IV |
| Name | Type | Description |
|---|---|---|
| granisetron transdermal system | DRUG | patch |
| Granisetron IV | DRUG | IV |
Inclusion Criteria: 1. 13 to 17 years of age inclusive at screening. 2. Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate. 3. Written patient assent (as appropriate). 4. Confirmed malignancy. 5. Scheduled to receive 2 or more cycles\* of ...